"Guardant and MSD collaborate on companion diagnostics development" was originally created and published by Hospital ...

Regulatory deregulation and liquid biopsy adoption pushing the rapid growth of the oncology companion diagnostic market. In ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with ...

Guardant Health is signing up to a multiyear deal with Merck & Co. for the U.S. Big Pharma to tap its Infinity Smart platform ...

The global companion diagnostics market is projected to grow at a robust CAGR of approximately 13% through 2031. This growth is driven by the increasing demand for personalized medicine, continuous ...

Never has there been more information to enable a patient’s fight against cancer, but how does one select the right treatment? This is how companion diagnostics fit with precision medicine. Advances ...

Personalized medicine is continuing to evolve to the point where we have drug makers developing drugs that come with a companion diagnostic, developed with the help of a diagnostic partner. Arno ...

Companion diagnostics in fields like oncology are well-known, but it’s their potential impact on psychiatry that is gaining attention and has the potential to shape the future of the industry.

Companion diagnostics play a crucial role in these treatments by helping healthcare providers personalize treatment plans based on individual patient characteristics. With the growing need for ...

The FDA has bestowed a green light to a companion diagnostic for Pfizer’s recently approved hemophilia B gene therapy—because, at a cost of $3.5 million per dose, you want to make sure it will work.